上皮性卵巢癌患者血小板增多对行二次肿瘤细胞减灭术预后影响

Effect of thrombocytosis on epithelial ovarian cancer patients treated using secondary cytoreductive surgery

目的有研究显示,血小板增多与上皮性卵巢癌(epithelial ovarian cancer,EOC)预后有相关性,本研究探讨血小板增多对EOC患者行二次肿瘤细胞减灭术(secondary cytoreductive surgery,SCS)的影响。方法回顾性分析2006-01-01-2015-12-31中国医科大学附属盛京医院收治的29例行SCS的EOC患者临床资料,分析血小板增多与患者临床病理特征的关系,及其对SCS手术效果及预后的影响。结果 29例患者中8例(27.6%)合并血小板增多,21例血小板正常。血小板增多与上皮性卵巢癌的FIGO分期(P=0.001)和术前血清CA125水平均呈负相关,P=0.03。合并血小板增多的SCS患者术后总生存时间为22.5个月,明显短于血小板正常者(46个月),P<0.05;合并血小板增多患者术后无瘤生存时间为19个月,明显短于血小板正常者(34个月),P<0.05。合并血小板增多患者术后残留病灶<1cm者2例,明显少于血小板正常者(14例),P<0.05。结论 EOC患者行SCS后,血小板增多患者术后残留病灶<1cm者较少,术后无瘤生存时间及总生时间明显缩短。

OBJECTIVE Studies showed that thrombocytosis is associated with prognosis of epithelial ovarian cancer.This study aimed to evaluate the resection range and prognostic value of thrombocytosis in epithelial ovarian cancer(EOC)patients treated using secondary cytoreduction surgery(SCS).METHODS Twenty-nine EOC patients with secondary cytoreduction surgery were retrospectively analyzed.The incidence of thrombocytosis was counted and its relationship with the clinical pathological feature was analyzed.The postoperative disease-free survival and overall survival time were analyzed.RESULTS Eight of 29(27.6%)patients showed thrombocytosis at primary diagnosis.Thrombocytosis was positively correlated with International Federation of Gynecology and Obstetrics(FIGO)stage(P=0.001)and CA125 level(P=0.03).Disease-free(19 months vs 34 months)and overall survival time(22.5 months vs 46 months)were both significantly shorter in patients with thrombocytosis than those without thrombocytosis(P=0.011;P=0.029).The number of cases with residual disease<1 cm in SCS patients with thrombocytosis(2 cases)was less than that of without thrombocytosis(14 cases,P<0.05).CONCLUSIONS After being treated by SCS,EOC patients with thrombocytosis have shorter overall survival and disease-free time.The number of cases with residual disease<1 cm in SCS patients with thrombocytosis is less.